Apellis Pharmaceuticals (APLS) saw a 17.6% surge in stock price after Scotiabank raised its price target to $22 from $20. This followed FDA approval of the company’s Empaveli treatment for kidney diseases. Citigroup also increased its price target to $46 with a “buy” recommendation. However, APLS widened its net loss in Q2 to $42.1 million.

Investors are eyeing Apellis Pharmaceuticals (APLS) as its stock continues to rise. With a surge of 17.6% on Thursday, reaching $22.34 per share, APLS stands out as a top performer. Following FDA approval of its Empaveli treatment, Scotiabank raised its price target to $22 and maintained a “sector perform” rating.

Apellis Pharmaceuticals, Inc. (APLS) received a price target increase from both Scotiabank and Citigroup, reaching $22 and $46, respectively. Despite widening its net loss in Q2 by 12%, APLS remains a promising investment. With total revenues down 10.6% year-on-year, the company’s stock performance is closely watched by investors.

Read more at Yahoo Finance: Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target